Close Menu

NEW YORK (360Dx) – NeoGenomics on Thursday priced its previously announced public offering of 9.8 million shares of its common stock at $12.75 per share.

Gross proceed from the offering are expected to be approximately $125 million.

NeoGenomics has granted the underwriters a 30-day option to purchase up to 1.47 million additional shares of common stock at the public offering price, less underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.

Apr
09
Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies.